Brokers Offer Predictions for AKRO Q3 Earnings

Key Points

• HC Wainwright expects Akero Therapeutics (NASDAQ:AKRO) to report Q3 2025 earnings of ($0.90) per share, maintaining a "Buy" rating with a target price of $72.00.
• Eight analysts currently hold a consensus rating of "Buy" for the stock, with an average price target of $81.14.
• Insider selling has been significant, with $10.1 million worth of shares sold over the last three months, representing a decrease in ownership for key insiders.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for Akero Therapeutics in a research note issued to investors on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.90) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $72.00 target price on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.61) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.73) EPS, FY2028 earnings at ($3.34) EPS and FY2029 earnings at ($1.65) EPS.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, August 8th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.97) by $0.11. During the same quarter in the prior year, the company earned ($0.81) EPS.

Other equities analysts have also recently issued research reports about the stock. Cowen initiated coverage on shares of Akero Therapeutics in a research note on Monday, August 4th. They set a "buy" rating on the stock. TD Cowen initiated coverage on shares of Akero Therapeutics in a research note on Monday, August 4th. They set a "buy" rating and a $76.00 target price on the stock. Bank of America raised their target price on shares of Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Finally, Wall Street Zen raised shares of Akero Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Akero Therapeutics currently has an average rating of "Buy" and an average target price of $81.14.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $0.41 during trading hours on Monday, reaching $44.53. The stock had a trading volume of 91,281 shares, compared to its average volume of 1,361,530. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.66 and a quick ratio of 12.66. Akero Therapeutics has a twelve month low of $21.34 and a twelve month high of $58.40. The firm has a 50-day simple moving average of $48.99 and a 200-day simple moving average of $46.56. The firm has a market capitalization of $3.56 billion, a PE ratio of -22.20 and a beta of -0.24.

Insider Buying and Selling at Akero Therapeutics

In other news, insider Catriona Yale sold 10,000 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $54.23, for a total transaction of $542,300.00. Following the completion of the transaction, the insider owned 92,231 shares in the company, valued at approximately $5,001,687.13. This trade represents a 9.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Andrew Cheng sold 30,000 shares of the firm's stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $51.16, for a total transaction of $1,534,800.00. Following the transaction, the chief executive officer owned 520,757 shares of the company's stock, valued at approximately $26,641,928.12. This trade represents a 5.45% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 160,692 shares of company stock worth $8,036,786. Company insiders own 7.07% of the company's stock.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new position in Akero Therapeutics during the second quarter valued at approximately $28,000. Northwest & Ethical Investments L.P. bought a new position in Akero Therapeutics during the first quarter valued at approximately $32,000. TD Waterhouse Canada Inc. bought a new position in Akero Therapeutics during the second quarter valued at approximately $71,000. Assetmark Inc. raised its position in shares of Akero Therapeutics by 152.9% in the second quarter. Assetmark Inc. now owns 1,439 shares of the company's stock valued at $77,000 after purchasing an additional 870 shares during the period. Finally, GF Fund Management CO. LTD. bought a new position in shares of Akero Therapeutics in the fourth quarter valued at approximately $41,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.